PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer - LARVOL DELTA

Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019-2022). (PubMed, Pneumonia (Nathan)) - "Despite paediatric vaccination with high coverage, we identified some residual PCV13 serotypes with predominance of non-PCV13 serotypes carried and causing disease in adults. Direct adult vaccination which targets these serotypes will potentially reduce disease in adults in Mongolia."

Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Pfizer | N=100 ➔ 200

Enrollment change • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (clinicaltrials.gov) - P1 | N=400 | Active, not recruiting | Sponsor: Pfizer | N=158 ➔ 400

Enrollment change • Infectious Disease • Pneumococcal Infections

Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia. (PubMed, Vaccine) - "This cost-effectiveness analysis estimated that adoption of PCV20 into the Australian paediatric NIP would be dominant versus PCV13 and PCV15, leading to health benefits and cost-savings."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan (ISPOR-EU 2025) - "CEA suggests use of PCV20—in lieu of current Taiwan CDC recommendations for pneumococcal vaccination in high-risk adults aged 18-64 years and all adults aged ≥65 years—would be cost saving and represent an efficient use of healthcare resources and would substantially reduce the numbers of cases and deaths due to pneumococcal disease."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants (ISPOR-EU 2025) - "Vaccine effectiveness (VE) was extrapolated from PCV13 effectiveness and PCV7 efficacy studies... PCV20 vaccination is projected to provide greater protection against pneumococcal disease in French infants than PCV15, regardless of VE assumptions or dosing schedules. These results support the preferential use of PCV20 to maximize disease prevention in the first year of life."

Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population (ISPOR-EU 2025) - "This study predicted that infant immunization with PCV20 was the most cost-effective option compared with PCV13 and PCV15. These results could help decision-makers implement the optimal PCV strategy in the French pediatric NIP."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Invasive Pneumococcal Disease at Eight Children's Hospitals in the United States, 2018-2023. (PubMed, Pediatr Infect Dis J) - "PCV13 serotypes (especially 3, 19A and 19F) continue to account for 30% of IPD in US children 8-13 years after PCV13 was introduced. Vancomycin should still be included in empiric treatment of bacterial meningitis in children. The introduction of PCV20 for routine administration to infants could result in further reductions in IPD in children."

Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections

Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India (ISPOR-EU 2025) - "Compared to PCV13 ◊PPV23, PCV20 in at-/high-risk older adults would be cost-saving and cost-effective from both private and government payer perspectives. Furthermore, from private payer perspective, PCV20 would be cost-effective compared with all other vaccination strategies considered."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay (ISPOR-EU 2025) - "Direct and indirect VE was derived from PCV7 and PCV13 clinical efficacy, effectiveness, and impact studies... PCV20 offers broader serotype coverage and was estimated to avert more PD cases and deaths than PCV13 and PCV15. Replacing lower-valent PCVs with PCV20 in the NIP was the most cost-saving and effective (dominant) option in Paraguay."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Public Health Impact of 25 Years of Pneumococcal Conjugate Vaccination in Children 5 Years Old: A Modeling Analysis (ISPOR-EU 2025) - "The vaccination of over 500 million infants with PCV7, PCV13, and PCV20 has substantially reduced the global burden of pneumococcal disease, preventing over 250 million cases and more than 1 million deaths over 25 years. Despite these achievements, pneumococcal disease remains a concern. Expanding PCV programs worldwide and implementing higher-valent PCVs in pediatric immunization programs could lead to greater reductions in disease burden."

Clinical • Infectious Disease • Pediatrics • Pneumococcal Infections

Healthcare providers' preferences for pediatric pneumococcal vaccination recommendations in the United States. (PubMed, Expert Rev Vaccines) - "93% of HCPs preferred PCV20 over PCV15 for children aged ≤18 years. HCPs' choices indicated a preference for the use of PCV20 in both a clinical setting and in pediatric pneumococcal vaccination recommendations, due to the higher number of serotypes covered by PCV20."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Cost-Effectiveness Analysis of Pediatric and Adult Pneumococcal Conjugate Vaccine Strategies in Canada (ISPOR-EU 2025) - "OBJECTIVES: In Canada, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20) are approved for use in adult and pediatric populations... Funding PCV20 for both pediatric and adult public immunization programs could result in greater health and economic gains than funding PCV15 in pediatric and PCV21 in adult programs. Additionally, using one vaccine for all ages could enhance equity, simplify vaccine procurement, and improve logistical inefficiencies related to training, supply, and storage."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population (ISPOR-EU 2025) - "Vaccinating with a single dose of PCV13 or PCV20 in targeted adult population in Kazakhstan is expected to significantly reduce clinical and economic burdens associated with PD."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections

Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants. (PubMed, Vaccine) - P3 | "Immune responses to routine pediatric vaccines given with PCV20 were noninferior to those when given with PCV13. PCV20 may be safely administered with other routine pediatric vaccines. (NCT04382326; NCT04546425)."

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Mumps • Pediatrics • Pertussis • Pneumococcal Infections • Respiratory Diseases • Rubella • Tetanus • Varicella Zoster

Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Hospitalization Burden in Norway (ISPOR-EU 2025) - "The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for higher-valent vaccine direct and indirect effect estimates... Replacing PCV13 with PCV20 in Norway's Childhood Immunisation Programme could significantly reduce hospital burden compared to replacing PCV13 with PCV15. These findings support the inclusion of PCV20 in national immunization schedules to reduce pneumococcal disease burden and associated hospital strain."

Clinical • Pneumococcal vaccines • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Impact of Real-World Effectiveness vs. Previous Assumptions on Estimates of Economic and Clinical Benefit of 20-Valent Pneumococcal Conjugate Vaccine in Adults Across Countries (ISPOR-EU 2025) - "Using PCV20 VE derived from real-world evidence predicts greater economic and clinical benefits compared to previous VE estimates used in economic models, suggesting existing economic models evaluating PCV20 in adults are likely conservative. Vaccine policy makers should incorporate available real-world effectiveness data when considering higher-valent PCVs for adults."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Antimicrobial Resistant Infections and Antibiotic Prescriptions in Greece (ISPOR-EU 2025) - "Widespread pediatric use of PCV20 in Greece can reduce AMR and antibiotic consumption. PCV20 implementation has the potential to substantially enhance public health in Greece while also helping to address the growing global challenge of AMR."

Clinical • Pneumococcal vaccines • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Supportive Care Gaps in Bronchiectasis Patients with NTM-PD: A Retrospective Study (WBC 2025) - "Pneumococcal vaccination uptake between 2018 and 2023 was similarly low, with 20.7% of bronchiectasis patients with NTMPD receiving either Prevenar 13 or Pneumovax® 23, compared to 15.9% of those without NTM-PD (p = 0.40). While bronchiectasis patients with NTM-PD have more frequent medical encounters, their access to supportive care remains inadequate. The clinical focus on diagnosing NTM and determining antimicrobial treatment needs may inadvertently overshadow supportive care, particularly physiotherapy and vaccinations. This represents a missed opportunity to provide comprehensive, patient-centered management that addresses both the infection and overall lung health."

Retrospective data • Bronchiectasis • Infectious Disease • Influenza • Nontuberculous Mycobacterial Disease • Pneumococcal Infections • Preventive care • Pulmonary Disease • Respiratory Diseases

Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines. (PubMed, Infect Dis Ther) - "A simplified model can effectively incorporate critical AMR parameters for a more comprehensive evaluation of PCVs. Our framework also identifies key data gaps that should be addressed for future modeling efforts."

Journal • Infectious Disease • Pneumococcal Infections

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants (clinicaltrials.gov) - P2 | N=388 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ Sep 2025 | Trial primary completion date: Jul 2026 ➔ Sep 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis. (PubMed, Hum Vaccin Immunother) - "We conducted a systematic review of observational studies published between 2006 and 2024 in mainland China, Hong Kong, and Taiwan to evaluate the effectiveness and impact of PCV7 and PCV13...Evidence for otitis media remained limited. These findings highlight the substantial health benefits of PCVs in Chinese children and underscore the importance of expanding vaccine utilization to reduce the burden of pneumococcal disease."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | N=54 ➔ 85

Checkpoint inhibition • Enrollment change • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Evaluation of T-Cell Responses Following Sequential Vaccination with PCV13 and PPSV23 Against Streptococcus pneumoniae in Patients with Psoriasis. (PubMed, Vaccines (Basel)) - "Immunosuppressive therapy alters vaccination-induced cellular immunity in psoriasis patients. Further research is needed to clarify the mechanisms involved."

Journal • Dermatology • Immunology • Infectious Disease • Pneumococcal Infections • Pneumonia • Psoriasis • IFNG • IL12A • IL17A • IL23A

The incremental net monetary benefit of higher-valent pneumococcal conjugate vaccines for adults: a systematic review and meta-analysis of economic evaluations. (PubMed, J Med Econ) - "PCV15 and PCV21 had few meta-analyzable comparisons.Conclusions Higher-valent PCVs appear cost-effective in most adult populations and settings, especially in high-income countries and from the healthcare perspective. This meta-analysis provides a rigorous quantitative synthesis to support vaccine policy decisions."

HEOR • Journal • Retrospective data • Review • Infectious Disease • Pneumococcal Infections